Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05036226 · ClinicalTrials.gov registry record · Phase 1

COAST Therapy in Advanced Solid Tumors and Prostate Cancer

A Phase 1 study of Solid Tumor, Adult and Prostate Cancer Recurrent, sponsored by Medical University of South Carolina.

Recruiting
Registry status
Phase 1
Development phase
76
Enrollment target
1
Study location

NCT05036226: Recruiting Phase 1 study of Solid Tumor, Adult and Prostate Cancer Recurrent, sponsored by Medical University of South Carolina.

NCT05036226 is a Phase 1 study of Solid Tumor, Adult and Prostate Cancer Recurrent that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 76 participants, below the 189-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05036226, a Phase 1 study of Solid Tumor, Adult and Prostate Cancer Recurrent, is actively recruiting participants, sponsored by Medical University of South Carolina.

RECRUITING
Registry status
Phase 1
Development phase
76 participants
Enrollment target
1
Study location

Study Summary

The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers. The drugs are hydroxychloroquine, metformin, sirolimus, dasatinib and nelfinavir and are given orally.

Primary Outcome

Maximum dose achievable without dose limiting toxicities (DLT's)

Interventions

  • COMBINATION_PRODUCT Hydroxychloroquine, Metformin, Sirolimus
  • COMBINATION_PRODUCT Hydroxychloroquine, Metformin, Sirolimus, Dasatanib
  • COMBINATION_PRODUCT Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir
  • COMBINATION_PRODUCT Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib

Study Locations (1)

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2022-03-03
Est. Completion 2027-05-21
Phase Phase 1

What NCT05036226 shows while recruiting

NCT05036226 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 189-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (60% lower).

The record links to 2 conditions, with Solid Tumor, Adult appearing as the primary indexed condition, and to 4 interventions - of which Hydroxychloroquine, Metformin, Sirolimus is the first listed.

NCT05036226 reports a single indexed study location in South Carolina.

Frequently Asked Questions

What is clinical trial NCT05036226 about?

NCT05036226 is a clinical study titled "COAST Therapy in Advanced Solid Tumors and Prostate Cancer". The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers. The drugs are hydroxychloroquine, metformin, sirolimus, dasatinib and nelfinavir and are given orally.

What is the current status of trial NCT05036226?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2022-03-03. Estimated completion is 2027-05-21.

What conditions does trial NCT05036226 study?

This clinical trial studies the following conditions: Solid Tumor, Adult, Prostate Cancer Recurrent.

What interventions are being tested in trial NCT05036226?

The interventions under investigation include: Hydroxychloroquine, Metformin, Sirolimus (COMBINATION_PRODUCT), Hydroxychloroquine, Metformin, Sirolimus, Dasatanib (COMBINATION_PRODUCT), Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir (COMBINATION_PRODUCT), Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05036226?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05036226 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Solid Tumor, Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05036226's enrollment target sits among peer trials

76 51st of 72 higher than 22 of 72 other Solid Tumor, Adult trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumor, Adult trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02615184 · 76 participants · Phase 2

    A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

  • NCT02821741 · 76 participants · NA

    Effects of External Ear Stimulation on Pain Perception and Mood

  • NCT03019757 · 76 participants

    Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

  • NCT03353584 · 76 participants · NA

    Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05036226, the US trial registry maintained by the National Library of Medicine. NCT05036226 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.